The present disclosure relates to heterocyclic compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.
本公开涉及
杂环化合物,其药用可接受盐以及其制药制剂。还描述了此类化合物的组成以及在治疗由CFTR活性缺陷介导的疾病和症状的方法中的使用,特别是囊性纤维化。